Novartis-owned Avidity Biosciences is currently evaluating del-brax in a recruiting Phase III study in FSHD.

Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology, today announced a collaboration with ...

Novartis (SWX:NOVN) reported breakthrough Phase III results for Rhapsido (remibrutinib) in chronic inducible urticaria, with ...

Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an ...

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met ...

University of Iowa to use Bionano-based assay to replace most “gold standard” Southern blot tests for molecular diagnosis of FSHD SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.

Swiss pharma Novartis (NOVN: VX) said its investigational RNA therapy del-brax has met the primary and key secondary ...

Novartis ( (NVS)) has issued an update. On June 11, 2026, Novartis reported that the biomarker cohort of its FORTITUDE Phase I/II trial of delpacibart braxlosiran (del-brax) in facioscapulohumeral ...

New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is associated with meaningful improvements in muscle mass, strength, and mobility ...

Facioscapulohumeral muscular dystrophy (FSHD1A, OMIM#158900) is the third most common hereditary muscle disease after Duchenne muscular dystrophy and myotonic dystrophy, with an estimated prevalence ...

– Demonstrated potential of FSHD-TUG and Emerald in-home assessments as accurate, low-burden clinical assessments of mobility for FSHD patients – – Company on track to report data from Phase 2b ReDUX4 ...